| Name: | Apremilast EP Impurity E |
| Catalogue No. | VL6770005 |
| CAS No. | 2487573-03-3 |
| Molecular Formula | C22H24N2O7S |
| Molecular Weight | 460.5 g/mol |
| Status | In-Stock |
| IUPAC Name | N-(2-(1-(4-ethoxy-3-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide |
| Synonyms | rac-4’-O-Ethyl-3’-O-methyl Apremilast |
| Description | Apremilast EP Impurity E (CAS NO.-2487573-03-3) IUPAC Name-N-(2-(1-(4-ethoxy-3-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. Apremilast is an oral phosphodiesterase 4 inhibitors that have an impact on a wide range of inflammatory mediators involved in psoriasis and psoriatic arthritis, this is the novel treatment that focuses on maintaining a balance between pro-inflammatory and anti-inflammatory signals. |
| References | Schafer, Peter. “Apremilast Mechanism of Action and Application to Psoriasis and Psoriatic Arthritis.” Biochemical Pharmacology, vol. 83, no. 12, June 2012, pp. 1583–90, https://doi.org/10.1016/j.bcp.2012.01.001. |
